110 Results for "

PC3 prostate cancer cells

" in MedChemExpress (MCE) Product Catalog:
Products (110)

110 Results for "PC3 prostate cancer cells" in MCE Product Catalog:

115
115 Publications Verification
Cat. No.: HY-10231
CAS No.: 685898-44-6
Purity:  ≥98.0%
PX-478 is a multifunctional HIF-1α inhibitor with properties including radiosensitization, autophagy activation, and lipid accumulation inhibition. PX-478 also blocks hypoxia-induced VEGF production and regulates β-cell phenotypes under hypoxic conditions. PX-478 induces cell cycle arrest and DNA damage, restores autophagic function, reduces foam cell formation, and maintains glucose homeostasis. PX-478 is widely used in research on related diseases such as human tumors (e.g., prostate cancer), type 2 diabetes, and atherosclerosis .
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-12364
CAS No.: 218137-86-1
Purity:  99.91%
C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM . C75 is a potent CPT1A activator .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-A0287
CAS No.: 911-45-5
Synonyms: Clomifene; (Z/E)-Enclomiphene; (Z/E)-Enclomifene
Target:  

Estrogen Receptor/ERR

Research Areas:  

Metabolic Disease Cancer

Clomiphene (Clomifene; (Z/E)-Enclomiphene; (Z/E)-Enclomifene) is an orally active ovulation-inducing agent. Clomiphene binds to hypothalamic estrogen receptors to elevate FSH levels, and exhibits antiestrogenic or estrogenic properties. Clomiphene can induce erturbations during meiotic maturation and cytogenetic abnormalities in mouse oocytes. Clomiphene ameliorates memory impairment in PCOS models. Clomiphene mobilizes cytosolic calcium and reduces viability in prostate cancer cells. Clomiphene can be used for the research of polycystic ovary syndrome (PCOS) and prostate cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-101017
CAS No.: 6865-14-1
Purity:  ≥98.0%
Palmitoylcarnitine chloride is a C16:0 long-chain acylcarnitine and an intermediate product of fatty acid oxidation. The level of Palmitoylcarnitine chloride in human prostate cancer tissues is higher than that in non-cancerous tissues. Palmitoylcarnitine chloride can be used in studies related to lipid metabolism associated with prostate cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-126357
CAS No.: 1935-18-8
Palmitoylcarnitine is a C16:0 long-chain acylcarnitine and an intermediate product of fatty acid oxidation. The level of Palmitoylcarnitine in human prostate cancer tissues is higher than that in non-cancerous tissues. Palmitoylcarnitine can be used in studies related to lipid metabolism associated with prostate cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-16160
CAS No.: 851636-83-4
Target:  

Autophagy ICMT

Research Areas:  

Neurological Disease Cancer

Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-160528
IBG3 is a bivalent molecular glue degrader that targets BRD2 and BRD4, with an EC50 of 32 nM and a Kd of 0.6 µM against human BRD4. IBG3 exhibits selectivity for BRD2 and BRD4 over BRD3. By recruiting the DCAF16 E3 ligase, IBG3 cis-binds to the tandem bromodomains of BRD2 and BRD4, enhances BRD-DCAF16 binding affinity, promotes ubiquitination and proteasomal degradation, and does not degrade isolated bromodomains. IBG3 lacks degradation selectivity for PSMA-positive and PSMA-negative prostate cancer cells, but shows lower in vivo antitumor efficacy than the PSMA-targeting conjugate IBG-P3, and can be used in prostate cancer-related research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N2415
CAS No.: 477-49-6
Podophyllotoxone is isolated from the roots of Dysosma versipellis and has anti-cancer activities.Podophyllotoxone is able to inhibit the tubulin polymerization .
loading...
    loading...
Cat. No.: HY-153910
CAS No.: 2316782-88-2
Purity:  99.74%
Target:  

Others

Research Areas:  

Cancer

AGPS-IN-1 (Compound 2i) is an effective AGPS binder. AGPS-IN-1 reduces ether lipids levels and cell migration rate. AGPS-IN-1 inhibits epithelial-mesenchymal transition (EMT) in prostate PC-3 and breast MDA-MB-231 cancer cells .
loading...
    loading...
Cat. No.: HY-130709
CAS No.: 2408641-24-5
Purity:  99.85%
Target:  

PROTACs CDK

Research Areas:  

Cancer

PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC50=62 nM) and CDK9 (DC50=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC50=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand .
loading...
    loading...
Cat. No.: HY-107582
CAS No.: 1354359-53-7
Purity:  99.54%
Research Areas:  

Cancer

JW480 is a selective KIAA1363/AADACL1 inhibitor with oral activity, featuring IC50 values of 12 nM against human KIAA1363, 20 nM against mouse KIAA1363. JW480 blocks lipid deacetylase activity to restrain HAG metabolism and lowers retinyl ester hydrolase function in hepatic stellate cells. JW480 reduces MAGE lipid levels and inhibits migration, invasion, survival and tumor growth of prostate cancer cells. JW480 lowers PKCδ phosphorylation, facilitates HAGP accumulation, diminishes platelet aggregation, dense granule secretion and Ca 2+ flux, delays arterial thrombosis and prolongs tail bleeding time in rats. JW480 can be used for the study of prostate cancer and thrombosis .
loading...
    loading...
Cat. No.: HY-171616
CAS No.: 878949-21-4
Target:  

HSP β-catenin

Research Areas:  

Cancer

DCEM1 binds to heat shock protein 60 (HSP60) and inhibits the interaction of HSP60 with ClpP, thereby blocking the mitochondrial unfolded protein response. DCEM1 inhibits β-catenin expression and ATP production in PC-3 and TKO cells. DCEM1 can be used in prostate cancer research .
loading...
    loading...
Cat. No.: HY-138555
CAS No.: 3026420-38-9
Purity:  99.45%
Research Areas:  

Cancer

PROTAC BRD4 Degrader-8 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC50s of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells .
loading...
    loading...
Cat. No.: HY-B1817
CAS No.: 557-34-6
Zinc acetate acts as an immune response modulator. Zinc acetate enhances the expression of HSP-70 mRNA. Zinc acetate restores the proliferation and cytokine production capacities of splenocytes. Zinc acetate reduces the Apoptosis level of splenocytes in endotoxemic mice. Zinc acetate increases plasma zinc levels and improves survival rates in mice with LPS-induced lethal endotoxemia. Zinc acetate induces rapid death of prostate cancer cell lines in vitro. Zinc acetate inhibits the growth of prostate cancer xenografts in SCID mice. Zinc acetate can be used in endotoxemia research .
loading...
    loading...
Cat. No.: HY-B1817A
CAS No.: 557-34-6
Synonyms: Zinc(II) acetate, 99.99% trace metals basis
Zinc (Zinc (II)) acetate, 99.99% trace metals basis is a heme oxygenase 1 (HO-1) activator and apoptosis inducer with cytotoxic and anticancer activities. Zinc acetate, 99.99% trace metals basis enhances HO-1 expression, alters the microRNA profile, and increases the level of caspase-cleaved cytokeratin 18. Zinc acetate, 99.99% trace metals basis also regulates the expression of Cdk2/cyclin E and interferes with cell cycle progression. Zinc acetate, 99.99% trace metals basis effectively inhibits cancer cell proliferation and induces their rapid death, with no significant cytotoxicity to non-tumor tissues. Zinc acetate, 99.99% trace metals basis has been widely used in studies related to hepatocellular carcinoma, prostate cancer, and other conditions .
loading...
    loading...
Cat. No.: HY-143883
CAS No.: 2376137-41-4
Target:  

PROTACs Akt

Research Areas:  

Cancer

MS143 is a VHL-recruiting AKT protein PROTAC degrader with a DC50 of 46 nM in PC3 prostate cancer cells. MS143 preferentially binds to AKT1 and AKT3, with weaker binding activity towards AKT2. MS143 degrades AKT and blocks the phosphorylation of downstream signaling molecules in the PI3K/AKT/mTOR pathway. MS143 inhibits cancer cell growth and xenograft tumor growth. MS143 can be used for research on prostate cancer, triple-negative breast cancer, and breast cancer .
loading...
    loading...
Cat. No.: HY-102067
CAS No.: 294891-81-9
Target:  

Wnt

Research Areas:  

Cancer

3289-8625 is an inhibitor of the PDZ domain of Dishevelled (Dvl) protein (Kd=10.6 μM) and has an inhibitory effect on Wnt signaling. In addition, 3289-8625 can slow the growth of prostate cancer PC-3 cells (IC50=12.5 μM). 3289-8625 can be used in the study of embryonic development and cancer .
loading...
    loading...
Cat. No.: HY-122678
CAS No.: 354543-09-2
Purity:  97.13%
Target:  

Survivin Apoptosis

Research Areas:  

Cancer

LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC50s of 2.99 and 2.47 µM, respectively .
loading...
    loading...
Cat. No.: HY-12929
CAS No.: 1629908-92-4
Purity:  99.86%
Synonyms: SU093
Target:  

Pim Apoptosis

Research Areas:  

Cancer

NSC756093 (SU093) is a GBP1:PIM1 interaction inhibitor. NSC756093 binds to GBP1-PIM1 with a Kd of 38 nM. NSC756093 suppresses proliferation, reduces migration, induces G1 phase cell-cycle arrest, and increases apoptotic cell death in ovarian cancer cells. NSC756093 reduces cellular proteasomal activity, induces accumulation of ubiquitinated proteins, and restrains tumor progression and lung metastasis in murine ovarian cancer xenograft models. NSC756093 increases sensitivity of prostate cancer cells to Docetaxel (HY-B0011) and sensitizes GBP1-overexpressing ovarian cancer cells to Paclitaxel (HY-B0015). NSC756093 can be used for the research of prostate cancer and ovarian cancer .
loading...
    loading...
Cat. No.: HY-N8210
CAS No.: 446-71-9
Homoeriodictyol is an orally active, bitter-tasting flavanone that can penetrate the blood-brain barrier. Homoeriodictyol enhances synaptic-related protein expression through NCOA4-mediated ferritin autophagy. Homoeriodictyol improves memory impairment in mice by inhibiting the NLRP3 inflammasome. Homoeriodictyol protects human endothelial cells from oxidative damage by activating Nrf2 and inhibiting mitochondrial dysfunction. Homoeriodictyol enhances ROS activity and induces apoptosis, exhibiting anticancer effects. Homoeriodictyol inhibits the survival and migration of androgen-resistant prostate cancer cells in vitro. Homoeriodictyol exerts antinociceptive activity in mice in vivo .
loading...
    loading...